Cubist to Feature Antibiotic Development Program at Inaugural IDWeek Annual Meeting

Before you go, we thought you'd like these...
Before you go close icon

Cubist to Feature Antibiotic Development Program at Inaugural IDWeek Annual Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NAS: CBST) today provided an overview of selected studies that will be presented at IDWeek, the first combined meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS), taking place taking place from October 17th to 21st in San Diego. The studies focus on the company's late-stage investigational antibiotic, CXA-201 (ceftolozane/tazobactam), as well as on CUBICIN® (daptomycin for injection).

"The data we are presenting at IDWeek underscore the potential of our late-stage pipeline as well as broaden our understanding of the clinical importance of CUBICIN," said Cubist's Chief Scientific Officer Steve Gilman, PhD. "We are pleased that these new in vitro data on CXA-201 continue to show a promising profile of activity and we look forward to the results of the pivotal Phase 3 studies."


A list of selected presentations can be found on the company's website. Key highlights include:

CXA-201 (ceftolozane/tazobactam)
CXA-201, a novel cephalosporin in combination with tazobactam, is in development for the treatment of certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms, particularly Pseudomonasaeruginosa and those in the Enterobacteriaceae family.

This year at IDWeek, two important studies on CXA-201 will be presented. In these two studies, CXA-201 showed significant potency in vitro when tested against Enterobacteriaceae and P. aeruginosa strains from hospitals in the United States or Canada.

Activity of the Novel Antimicrobial Combination Ceftolozane/Tazobactam, Tested Against Bacterial Isolates in USA Hospitals from Patients with Pneumonia (2011) (Presentation 846) Friday, October 19, 2012, 12:30 p.m. - 2:00 p.m. PDT, Poster Hall F-H.

in VitroActivity of Ceftolozane/Tazobactam versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals: CANWARD 2011 (Presentation 1616) Saturday, October 20, 2012, 12:30 p.m. - 2:00 p.m. PDT, Poster Hall F-H.

CUBICIN (daptomycin for injection)
Thirteen scientific abstracts at IDWeek feature daptomycin. New data on at-home infusion of daptomycin compared to vancomycin are presented. These new data show that adverse event rates were similar between the two therapies. Another important study outlines key pharmacokinetic parameters and dosing implications in pediatric patients.

Safety and Clinical Outcomes of Daptomycin at Doses of ≥10 mg/kg (Presentation 779) Friday, October 19, 2012, 12:30 p.m. - 2:00 p.m. PDT, Poster Hall F-H.

Adverse Events and Healthcare Utilization during Home Infusion Therapy with Daptomycin and Vancomycin (Presentation 794) Friday, October 19, 2012, 12:30 p.m. - 2:00 p.m. PDT, Poster Hall F-H.

Pharmacokinetics of Daptomycin in Pediatric Patients 3 to 24 Months of Age: Implications for Dosing (Presentation 788) Friday, October 19, 2012, 12:30 p.m. - 2:00 p.m. PDT, Poster Hall F-H.

About CUBICIN
CUBICIN® (daptomycin for injection) is approved in the U.S. and many other non-US markets as therapy for Staphylococcus aureus bloodstream infections (bacteremia), including right-sided endocarditis, caused by methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA), and complicated skin infections caused by certain Gram-positive bacteria, including MRSA. CUBICIN is not indicated for the treatment of pneumonia. Most adverse events reported in clinical trials were mild to moderate in intensity. The most common were anemia, constipation, diarrhea, nausea, vomiting, injection site reactions, and headache. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN, CUBICIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria susceptible to CUBICIN. For full prescribing information, including important safety information, please visit www.cubicin.com.

About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist's web site at www.cubist.com.



INVESTORS:
Cubist Pharmaceuticals, Inc.
Eileen C. McIntyre, 781-860-8533
Senior Director, Investor Relations
eileen.mcintyre@cubist.com
or
MEDIA:
Francis McLoughlin, 781-860-8777
Director, Corporate Communications
Francis.mcloughlin@cubist.com

KEYWORDS:   United States  North America  California  Massachusetts

INDUSTRY KEYWORDS:

The article Cubist to Feature Antibiotic Development Program at Inaugural IDWeek Annual Meeting originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners